This promotional website has been developed, organised and funded by Boehringer Ingelheim.
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
Podcasts
- PODCAST - Episode 1
- 30 min
Managing type 2 diabetes in the elderly and frail
- LISTEN TO THE GREAT BRITAIN & NORTHERN IRELAND PODCAST
PC-GB-104056 I NOVEMBER 2021
CLICK HERE TO DOWNLOAD REFERENCE LIST
- CLICK HERE TO LISTEN TO THE REPUBLIC OF IRELAND PODCAST
PC-IE-101327 I AUGUST 2021
- PODCAST - Episode 2
- 32 min
Effective management of type 2 diabetes in adults: The role of individualised patient care
- LISTEN TO THE GREAT BRITAIN & NORTHERN IRELAND PODCAST
PC-GB-105127 I NOVEMBER 2021
CLICK HERE TO DOWNLOAD REFERENCE LIST
- CLICK HERE TO LISTEN TO THE REPUBLIC OF IRELAND PODCAST
PC-IE-101328 I AUGUST 2021
- PODCAST - Episode 3
- 25 min
COVID-19 and type 2 diabetes: What have we learned and where should our focus be moving forward?
- PODCAST - Episode 3
- 27 min
Start the conversation early: Actively support your adult patients with type 2 diabetes during Ramadan
Webinar
Sarah Jarvis
Kevin Fernando
The event starts in:
How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?
Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients
- 27 September 2023
- 13:00 & 19:00
- VIRTUAL WEBINAR
- 27 September 2023
Webinar
Sarah Jarvis
Kevin Fernando
The event starts in:
Coming soon
Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients
- 27 September 2023
- 13:00 & 19:00
- VIRTUAL WEBINARS
- 27 September 2023
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.
PC-GB-106626 V3 | August 2023
